Source: The Press Association
The U.K. Department of Health is working with manufacturers to resolve supply problems involving its typhoid fever vaccination stocks. Healthcare providers are returning Typhim Vi to French manufacturer Sanofi Pasteur as part of a recall resulting from concerns over whether the vaccine is potent enough. The recall involves 16 batches of the vaccine, distributed from Jan. 7, 2011. Typhim Vi accounts for 88 percent of the U.K. market for typhoid fever vaccination, and more than half a million people in England get the shot each year. “There are no concerns over the safety of this vaccine but the recall has taken place because the vaccine may not be as effective as it should be,” said Ian Holloway, head of the defective medicines report center at The Medicines and Healthcare products Regulatory Agency.